TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15563390

Group type: EXPERIMENTAL
Intervention: Operative treatment (extended lateral approach with subchondral fixation, plating, and bone grafting when necessary)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Nonoperative treatment (ice, elevation, and rest without closed reduction)
Number of subjects: 244
Study: 11403755

Group type: EXPERIMENTAL
Intervention: Excimer laser‐assisted recanalization and stent implantation
Number of subjects: 212
Study: 9153347

Group type: EXPERIMENTAL
Intervention: Fasting administration of 400 mg racemic ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postprandial administration of 400 mg racemic ibuprofen
Number of subjects: 0
Study: 7955240

Group type: EXPERIMENTAL
Intervention: Rastelli operation or intraventricular repair
Number of subjects: 24
Study: 3608379

Group type: EXPERIMENTAL
Intervention: Chlorpropamide 250 mg twice daily for 2 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29460783

Group type: EXPERIMENTAL
Intervention: Zùsto®
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucose 25 g
Number of subjects: 10
Study: 26850799

Group type: EXPERIMENTAL
Intervention: Reflexology (10 min on each foot)
Number of subjects: 12
Study: 25658956

Group type: EXPERIMENTAL
Intervention: Tasimelteon 20 mg capsule
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tasimelteon 2 mg IV infusion over 30 minutes
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both treatments (oral and IV)
Number of subjects: 14
Study: 23746291

Group type: EXPERIMENTAL
Intervention: Adaptive probabilistic modeling of EEG background for seizure detection
Number of subjects: 89
Study: 20377407

Group type: EXPERIMENTAL
Intervention: Reduced-dose (9 microg, 0.3 mL) ID injection
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Reduced-dose (9 microg, 0.3 mL) IM injection
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Standard-dose (15 microg each of 3 hemagglutinin vaccine antigens in 0.5 mL) IM injection
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Two reduced-dose (4.5 microg, 0.15 mL) ID injections
Number of subjects: 257
Study: 18540358

Group type: EXPERIMENTAL
Intervention: Steroid pulse therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apheresis therapy (Plasmapheresis and Cytapheresis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoadsorption plasmapheresis (IAPP)
Number of subjects: 0
Study: 16796986

Group type: COMPARATOR
Intervention: 21/7 oral contraceptive regimen
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 168-day extended regimen of DRSP/EE
Number of subjects: 114
Study: 15258964

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF)
Number of subjects: 4
Study: 11122141

Group type: EXPERIMENTAL
Intervention: ATRA and chemotherapy (CT)
Number of subjects: 292
Study: 9308808

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic diagnosis (PGD) of aneuploidy for chromosomes X, Y, 13, 18, and 21
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Normal embryos transferred after PGD
Number of subjects: 36
Study: 8319667

Group type: EXPERIMENTAL
Intervention: Iron-enriched milk (12 mg/l)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control milk (1 mg/l)
Number of subjects: 153
Study: 3105357

Group type: EXPERIMENTAL
Intervention: RO 15‐1788
Number of subjects: 7

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30995895

Group type: EXPERIMENTAL
Intervention: Half saline-bicarbonate infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study: 30146142

Group type: EXPERIMENTAL
Intervention: ePST (computer-guided Problem-Solving Treatment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: MCC (minimal contact control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ePST
Number of subjects: 24
Study: 27236864

Group type: EXPERIMENTAL
Intervention: 1 g of intravenous acetaminophen every 6 hours for 24 hours
Number of subjects: 147

Group type: COMPARATOR
Intervention: Comparable placebo
Number of subjects: 147
Study: 25531109

Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (80 mg)
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Low dose atorvastatin (10 mg)
Number of subjects: 1506
Study: 22158433

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 20477781

Group type: EXPERIMENTAL
Intervention: B-vitamin plus nitrous oxide
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo plus nitrous oxide
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo plus air
Number of subjects: 63
Study: 18539358

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate emulsion foam 0.05%
Number of subjects: 958

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 958
Study: 15841830

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for depressed older adults
Number of subjects: 34
Study: 12562348

Group type: EXPERIMENTAL
Intervention: Honey-impregnated gauzes
Number of subjects: 88

Group type: COMPARATOR
Intervention: Paraffin gauzes
Number of subjects: 88

Group type: COMPARATOR
Intervention: Saline-soaked gauzes
Number of subjects: 88

Group type: COMPARATOR
Intervention: Hydrocolloid dressings
Number of subjects: 88
Study: 9426297

Group type: EXPERIMENTAL
Intervention: 3 a.m. testing
Number of subjects: 10

Group type: COMPARATOR
Intervention: 8 a.m. testing
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3 p.m. testing
Number of subjects: 10

Group type: COMPARATOR
Intervention: 8 p.m. testing
Number of subjects: 10
Study: 8830068

Group type: EXPERIMENTAL
Intervention: Clonidine plus haloperidol (20 mg/day)
Number of subjects: 12
Study: 2919772

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 2 mg butorphanol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25% bupivacaine + 0 mg butorphanol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 3 mg butorphanol
Number of subjects: 40
Study: 31996813

Group type: EXPERIMENTAL
Intervention: 0.3% NaCl solution with 0.3% MSG
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: 0.6% NaCl solution with 0.3% MSG
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: 0.9% NaCl solution with 0.3% MSG
Number of subjects: 584

Group type: COMPARATOR
Intervention: 0.3% NaCl solution without MSG
Number of subjects: 584

Group type: COMPARATOR
Intervention: 0.6% NaCl solution without MSG
Number of subjects: 584

Group type: COMPARATOR
Intervention: 0.9% NaCl solution without MSG
Number of subjects: 584
Study: 29855444

Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 16
Study: 28708734

Group type: EXPERIMENTAL
Intervention: 0.1‐mmol/kg bw of gadoterate (full dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.05‐mmol/kg bw of gadobenate (half dose)
Number of subjects: 40
Study: 25089928

Group type: EXPERIMENTAL
Intervention: Cangrelor infusion (bolus plus 2-h infusion)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg dose at 1h, 1.5h, 2h, or 2.5h after cangrelor)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg daily for 5 or 6 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cangrelor infusion (on study day 8)
Number of subjects: 15
Study: 23949478

Group type: EXPERIMENTAL
Intervention: Laparoscopic paraesophageal hernia repair (LPEHR) in group A (acute)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Laparoscopic paraesophageal hernia repair (LPEHR) in groups A, B, and C
Number of subjects: 269
Study: 21223498

Group type: EXPERIMENTAL
Intervention: Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) screening tool
Number of subjects: 2480
Study: 19341849

Group type: EXPERIMENTAL
Intervention: One cycle of pills at initiation, followed by counseling and a three-pack resupply
Number of subjects: 655

Group type: COMPARATOR
Intervention: Four packs at initiation
Number of subjects: 655
Study: 17986694

Group type: EXPERIMENTAL
Intervention: Tezosentan (5 mg/h for 30 minutes, followed by 1 mg/h for 24 to 72 hours)
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 1435
Study: 15513364

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 724
Study: 11695951

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg/d for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9663244

Group type: EXPERIMENTAL
Intervention: Autotransplantation of 60 mg of a diffuse hyperplastic parathyroid gland into subcutaneous forearm tissue (Group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Autotransplantation of 15 pieces (60 mg) of 1 mm3 tissue into forearm muscles (Group B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Calcium carbonate and calcitriol prescribed post-operation
Number of subjects: 46
Study: 8148460

Group type: EXPERIMENTAL
Intervention: poly(I).poly(C12U)
Number of subjects: 92
Study: 3542628

Group type: EXPERIMENTAL
Intervention: Fenticonazole
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 54
Study: 29518703

Group type: EXPERIMENTAL
Intervention: Tailored driving lessons (two one-hour lessons)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Road rules refresher course only (control group)
Number of subjects: 57
Study: 26036929

Group type: EXPERIMENTAL
Intervention: Patient-centred nutrition intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 24866357

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (PR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 58
Study: 22375580

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention group (n = 204)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Vegetable and Fruit (VF) intervention group (n = 106)
Number of subjects: 310
Study: 20629484

Group type: EXPERIMENTAL
Intervention: Patients with mild traumatic brain injury (MTBI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients with MTBI
Number of subjects: 43
Study: 18179466

Group type: EXPERIMENTAL
Intervention: Children of immigrants
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Caregiver language preference
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Immigrant status and language preference
Number of subjects: 283
Study: 18027541

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 50
Study: 15613018

Group type: EXPERIMENTAL
Intervention: 150 mg quercetin‐4'‐O‐beta‐D‐glucoside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg quercetin‐4'‐O‐beta‐D‐glucoside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Collagen-stimulated platelet activation
Number of subjects: 0
Study: 10637204

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of carbachol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of L-NMMA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of carbachol followed by coinfusion with L-NMMA
Number of subjects: 24
Study: 9314339

Group type: EXPERIMENTAL
Intervention: Active treatment (ragweed immunotherapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (initial immunotherapy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (symptom diaries)
Number of subjects: 20
Study: 7680641

Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention (supplemental in-hospital education followed by telephone contact from discharge to eighth week after discharge)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 156
Study: 3954126

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study: 29658831

Group type: EXPERIMENTAL
Intervention: Short-burst interval locomotor treadmill training (SBLTT)
Number of subjects: 12
Study: 28257614

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cortisone Injection
Number of subjects: 43

Group type: COMPARATOR
Intervention: Medication intake for pain
Number of subjects: 43
Study: 25361981

Group type: EXPERIMENTAL
Intervention: Low-ER receptor signaling and apoptosis gene module scores
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High AKT-MTOR, Ras, and β-catenin module scores
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Basal-like subtype
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: HER2-enriched subtype
Number of subjects: 111

Group type: COMPARATOR
Intervention: Luminal A subtype
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Overall distribution of subtypes
Number of subjects: 111
Study: 24289059

Group type: EXPERIMENTAL
Intervention: New Medicine Service (NMS) intervention comprising pharmacist-delivered support for a newly prescribed medicine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 250
Study: 21828126

Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (HD-DN, 90 mg/m² per day times 3 days)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Standard-dose daunorubicin (SD-DN, 45 mg/m² per day times 3 days)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (HD-DN)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Standard-dose daunorubicin (SD-DN)
Number of subjects: 383
Study: 19214363

Group type: EXPERIMENTAL
Intervention: Spanish version of the PFIQ
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Spanish version of the PFDI
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Spanish version of both questionnaires
Number of subjects: 44
Study: 16674198

Group type: EXPERIMENTAL
Intervention: Mathematical model applied to in vivo fluorescence measurements
Number of subjects: 292
Study: 15116990

Group type: EXPERIMENTAL
Intervention: Encoding-speeded response (ESR) paradigm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychological refractory period (PRP) paradigm
Number of subjects: 0
Study: 11417033

Group type: EXPERIMENTAL
Intervention: Proprietary sodium stibogluconate (Pentostam, PSM)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Generic sodium stibogluconate (SSG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 102
Study: 9340641

Group type: EXPERIMENTAL
Intervention: Alcohol (1.5 ml per kg of body weight of 80 proof vodka)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nCPAP pressure determination by AutoSet
Number of subjects: 10
Study: 8343351

Group type: EXPERIMENTAL
Intervention: Fibrin glue applied intraoperatively
Number of subjects: 24

Group type: COMPARATOR
Intervention: No complementary treatment (Control)
Number of subjects: 24
Study: 3739798

Group type: EXPERIMENTAL
Intervention: Cognitive Rehearsal (Self‐instructional training)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Insight Control
Number of subjects: 94

Group type: COMPARATOR
Intervention: Individual Contact Control
Number of subjects: 94

Group type: COMPARATOR
Intervention: Group Contact Control (core programme only)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Initial weight loss
Number of subjects: 94
Study: 28976265

Group type: COMPARATOR
Intervention: Gr.Suppl.0 (control group) - no supplementation
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Gr.Suppl.5 - 5 µg daily dose of VitD3-fortified yogurt
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Gr.Suppl.10 - 10 µg daily dose of VitD3-fortified yogurt
Number of subjects: 133
Study: 27133029

Group type: EXPERIMENTAL
Intervention: Lanicemine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 24825853

Group type: EXPERIMENTAL
Intervention: ECG screening (experimental group)
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: False-positive results (experimental group)
Number of subjects: 952

Group type: COMPARATOR
Intervention: Standardised history and physical examination (control group)
Number of subjects: 952
Study: 22301333

Group type: EXPERIMENTAL
Intervention: Competition group (monetary reward for pain task trials performed)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no competing goal)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Competition group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 20487638

Group type: EXPERIMENTAL
Intervention: Manual chest physiotherapy (MCP)
Number of subjects: 526

Group type: COMPARATOR
Intervention: No MCP (Control)
Number of subjects: 526
Study: 18395907

Group type: EXPERIMENTAL
Intervention: Prepacol (sodium phosphate and bisacodyl) preparation in 26 patients
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no Prepacol preparation) in 26 patients
Number of subjects: 52
Study: 15562015

Group type: EXPERIMENTAL
Intervention: Calcium (500 mg twice daily with meals)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 11953691

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 73
Study: 9798657

Group type: EXPERIMENTAL
Intervention: Active treatment (Group A, n = 11)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (Group C, n = 36)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Total SS group (Groups A and B)
Number of subjects: 18
Study: 8559945

Group type: EXPERIMENTAL
Intervention: Imipramine with additional psychotherapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Doxepin with additional psychotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 2677292

Group type: EXPERIMENTAL
Intervention: Nutramigen
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cow milk
Number of subjects: 17
Study: 869086

Group type: EXPERIMENTAL
Intervention: Smoking withdrawal clinic protocols (various drugs and education methods)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Social and psychological characteristics
Number of subjects: 800
Study: 31676157

Group type: EXPERIMENTAL
Intervention: Residual hand sanitizer (quaternary ammonium‐based)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonresidual hand sanitizer (60% ethanol)
Number of subjects: 0
Study: 30959006

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.2 mg/kg (group MD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral melatonin 0.4 mg/kg (group M)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral multivitamin tablet as placebo (group P)
Number of subjects: 90
Study: 29336763

Group type: EXPERIMENTAL
Intervention: Daily chlorhexidine gluconate (CHG) baths and mupirocin (MUP) ointment to the nares
Number of subjects: 92

Group type: COMPARATOR
Intervention: Soap and water baths and placebo ointment
Number of subjects: 92
Study: 25707404

Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 20
Study: 24517052

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XC) 3 tablets thrice daily for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (routine anti‐rheumatic treatment: Methotrexate 10 mg/week; Diclofenac 50 mg twice daily when pain was obvious)
Number of subjects: 80
Study: 20713434

Group type: EXPERIMENTAL
Intervention: Endurance-exercise training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Resistance-exercise training
Number of subjects: 16
Study: 19558302

Group type: EXPERIMENTAL
Intervention: Scalp clips (Scalpfix, Aesculap)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Artery forceps
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Length of operation
Number of subjects: 150
Study: 16638738

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (rivaroxaban) 5 mg tablets (fasted and fed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (rivaroxaban) 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (rivaroxaban) 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (rivaroxaban) with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: BAY 59-7939 (rivaroxaban) with ranitidine (150 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BAY 59-7939 (rivaroxaban) with antacid (10 mL)
Number of subjects: 0
Study: 15598997

Group type: EXPERIMENTAL
Intervention: Group A - initial conservative treatment followed by interval appendectomy six weeks later
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B - appendectomy as soon as appendiceal mass resolved using conservative means
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group C - conservative treatment alone
Number of subjects: 60
Study: 11739971

Group type: EXPERIMENTAL
Intervention: Patients without border zone infarcts (n=26)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patients with border zone infarcts (n=25)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Collateral flow via the posterior communicating artery
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients with ICA occlusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 9709410

Group type: EXPERIMENTAL
Intervention: Substance P (2-8 pmol/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Substance P (2-8 pmol/min) with L-NMMA (1-4 micrograms/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: L-NMMA (1-4 micrograms/min) alone
Number of subjects: 8
Study: 8037263

Group type: EXPERIMENTAL
Intervention: Glycine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2919798

Group type: EXPERIMENTAL
Intervention: Potassium metabisulfite oral aqueous challenge
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13